<DOC>
	<DOCNO>NCT01458392</DOCNO>
	<brief_summary>Dalantercept , soluble form activin receptor-like kinase-1 protein , study patient squamous cell carcinoma head neck ( SCCHN ) . Dalantercept block development blood vessel supply tumor .</brief_summary>
	<brief_title>Study Dalantercept Patients With Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>For cancer cell grow , need nutrient supply blood vessel . The study drug , dalantercept , design work block growth blood vessel prevent cancer cell grow . The purpose study find dalantercept cause SCCHN tumor shrink stop growing . This study also evaluate safety dalantercept patient SCCHN .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Histologically and/or cytologically confirm , recurrent metastatic SCCHN mucosal origin ( oral cavity , oropharynx , hypopharynx larynx ) amenable local therapy ( surgery , radiation include reirradiation ) ; patient unknown primary SCCHN presume head neck mucosal origin eligible meet entry criterion . Previously treat least one platinumcontaining regimen contraindicate treatment platinum contain therapy . ( Note : platinum therapy occur upfront recurrence disease . Failure platinum therapy require . ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Key Nasopharyngeal carcinoma , paranasal sinus , salivary gland primary skin SCCHN . Any active malignancy chemotherapy anticancer therapy indicate . Chemotherapy anticancer therapy radiation therapy within 5 time halflife drug within 3 week prior study day 1 halflife know . Treatment another investigational drug device , approve therapy investigational use , within 5 time halflife drug within 3 week prior study day 1 halflife know . Major surgery within 4 week prior study day 1 ( patient must recover completely previous surgery prior study day 1 ) . Clinically significant cardiovascular risk . Clinically significant active pulmonary risk . Clinically significant active bleeding . Peripheral edema â‰¥ Grade 1 within 4 week prior study day 1 . Pregnant lactate female patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>